Prostate Cancer Drugs Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Prostate Cancer Drugs Market Size By 2025?
The market size of drugs for prostate cancer has seen a robust growth in the recent past. The market will expand from $18.53 billion in 2024 to $19.51 billion in 2025, with a compound annual growth rate (CAGR) of 5.3%. The significant growth in the historically can be credited to factors like an elderly population, increased number of diagnoses, drug development, heightened awareness and education, along with reimbursement and insurance.

How Big Is the Prostate Cancer Drugs Market Size Expected to Grow by 2029?
The market size for prostate cancer medications is projected to experience significant expansion in the coming years. The anticipated growth would reach "$24.63 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 6.0%. Forecasts attribute this robust growth to a higher incidence rate, budding markets, government policy support, and research & development investments. Several predominant trends during this projected timeline include the rise of precision medicine, personalized treatments, immunotherapy, targeted therapies, advancements in clinical trials and drug pipelines, combo therapies, biomarker-fueled treatments, as well as a surge in telemedicine and remote monitoring services.

View the full report here:
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Which Key Market Drivers Powering Prostate Cancer Drugs Market Expansion and Growth?
The growth of the prostate cancer drugs market is largely fueled by the escalating number of elderly men. Prostate cancer is predominantly prevalent in men over the age of 60, making it one of the most common cancer types in this demographic. The Administration for Community Living (ACL), a US government organization, predicts a 21.6% surge in the geriatric population by 2040. Prostate cancer significantly affects more males within this population than females. Highlighting this, the American Cancer Society, reported in January 2022 that prostate cancer primarily occurs in older men and non-hispanic black men, with roughly 60% of cases diagnosed in men aged 65 or older (the geriatric population). Hence, the rise in the geriatric male population propels the expansion of the prostate cancer market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2592&type=smp

What Are the Key Trends Driving Prostate Cancer Drugs Market Growth?
An emerging trend in the prostate cancer market involves the shift towards combination therapy, especially in cases where monotherapy has proven to be less effective. This is prompting pharmaceutical companies in the sector to allocate more resources towards combining treatments. For instance, Pfizer announced the successful results of its Phase 3 PROSPER trial for patients suffering from non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC). The findings highlighted that XTANDI (enzalutamide), when combined with androgen deprivation therapy (ADT), was able to cut down the risk of metastases or death by 71% compared to the use of ADT only. Comparable combination therapies such as radiation therapy combined with ADT for recurrent prostate cancer and the concurrent use of chemotherapy drug docetaxel (Taxotere) with ADT are other examples of treatments being utilized in the fight against prostate cancer.

What Are the Emerging Segments in the Prostate Cancer Drugs Market?
The prostate cancer drugs market covered in this report is segmented -

1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer
2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy
3) By End User: Hospitals, Clinics, Other End-Users

Subsegments:
1) By Hormone Sensitive Prostate Cancer: Early-Stage Prostate Cancer, Locally Advanced Prostate Cancer, Metastatic Prostate Cancer
2) By Hormone Refractory Prostate Cancer: Castration-Resistant Prostate Cancer (CRPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2592&type=smp

Who Are the Global Leaders in the Prostate Cancer Drugs Market?
Major companies operating in the prostate cancer drugs market include Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG, F. Hoffmann-La Roche AG, Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp., Dendreon Corporation, Ferring Pharmaceuticals Inc., GlaxoSmithKline plc, Ipsen Biopharmaceuticals Inc., Merck & Co. Inc., Eli Lilly and Company Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., Biogen Inc., Celgene Corporation, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Agios Pharmaceuticals Inc., Exelixis Inc.

Which are the Top Profitable Regional Markets for the Prostate Cancer Drugs Industry?
North America was the largest region in the prostate cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the prostate cancer drugs market during the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2592

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.